Radium-223 for metastatic castration-resistant prostate cancer: results and remaining open issues after the ALSYMPCA trial

Detalles Bibliográficos
Autores principales: Heidegger, Isabel, Pichler, Renate, Heidenreich, Axel, Horninger, Wolfgang, Pircher, Andreas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2018
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5881202/
https://www.ncbi.nlm.nih.gov/pubmed/29644181
http://dx.doi.org/10.21037/tau.2017.10.06
_version_ 1783311273475178496
author Heidegger, Isabel
Pichler, Renate
Heidenreich, Axel
Horninger, Wolfgang
Pircher, Andreas
author_facet Heidegger, Isabel
Pichler, Renate
Heidenreich, Axel
Horninger, Wolfgang
Pircher, Andreas
author_sort Heidegger, Isabel
collection PubMed
description
format Online
Article
Text
id pubmed-5881202
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-58812022018-04-11 Radium-223 for metastatic castration-resistant prostate cancer: results and remaining open issues after the ALSYMPCA trial Heidegger, Isabel Pichler, Renate Heidenreich, Axel Horninger, Wolfgang Pircher, Andreas Transl Androl Urol Editorial AME Publishing Company 2018-03 /pmc/articles/PMC5881202/ /pubmed/29644181 http://dx.doi.org/10.21037/tau.2017.10.06 Text en 2018 Translational Andrology and Urology. All rights reserved.
spellingShingle Editorial
Heidegger, Isabel
Pichler, Renate
Heidenreich, Axel
Horninger, Wolfgang
Pircher, Andreas
Radium-223 for metastatic castration-resistant prostate cancer: results and remaining open issues after the ALSYMPCA trial
title Radium-223 for metastatic castration-resistant prostate cancer: results and remaining open issues after the ALSYMPCA trial
title_full Radium-223 for metastatic castration-resistant prostate cancer: results and remaining open issues after the ALSYMPCA trial
title_fullStr Radium-223 for metastatic castration-resistant prostate cancer: results and remaining open issues after the ALSYMPCA trial
title_full_unstemmed Radium-223 for metastatic castration-resistant prostate cancer: results and remaining open issues after the ALSYMPCA trial
title_short Radium-223 for metastatic castration-resistant prostate cancer: results and remaining open issues after the ALSYMPCA trial
title_sort radium-223 for metastatic castration-resistant prostate cancer: results and remaining open issues after the alsympca trial
topic Editorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5881202/
https://www.ncbi.nlm.nih.gov/pubmed/29644181
http://dx.doi.org/10.21037/tau.2017.10.06
work_keys_str_mv AT heideggerisabel radium223formetastaticcastrationresistantprostatecancerresultsandremainingopenissuesafterthealsympcatrial
AT pichlerrenate radium223formetastaticcastrationresistantprostatecancerresultsandremainingopenissuesafterthealsympcatrial
AT heidenreichaxel radium223formetastaticcastrationresistantprostatecancerresultsandremainingopenissuesafterthealsympcatrial
AT horningerwolfgang radium223formetastaticcastrationresistantprostatecancerresultsandremainingopenissuesafterthealsympcatrial
AT pircherandreas radium223formetastaticcastrationresistantprostatecancerresultsandremainingopenissuesafterthealsympcatrial

Ejemplares similares